Drug updated on 5/17/2024
Dosage Form | Injection (intravenous; 50 mg) |
Drug Class | Tissue plasminogen activators |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI).
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Tenecteplase (TNKase) is indicated to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI).
- Information was derived from 15 systematic reviews and meta-analyses.
- Both tenecteplase and alteplase show comparable outcomes in improving clinical endpoints such as early neurological improvement, excellent functional outcome, and recanalization rates post-treatment in AIS patients.
- The effectiveness of tenecteplase appears dose-dependent, with the 0.25 mg/kg dosage frequently cited as potentially more efficacious compared to alteplase in achieving excellent functional outcomes at three months.
- Studies report no significant differences between tenecteplase and alteplase in terms of safety outcomes like symptomatic intracranial hemorrhage and mortality rates.
- In patients presenting with acute tandem occlusions, tenecteplase's safety and efficacy were comparable to alteplase; however, incidents of any intracranial hemorrhage were more frequent with tenecteplase.
- Synthesized evidence suggests that tenecteplase offers a viable alternative to alteplase for treatment within 4.5 hours of symptom onset due to its pharmacokinetic profile, favoring single bolus administration, which might offer logistical benefits over alteplase.
- Tenecteplase stands out as a promising agent, mirroring or surpassing alteplase under certain clinical scenarios, emphasizing the importance of an optimal dosing strategy.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
TNKase (tenecteplase) Prescribing Information. | 2024 | Roche Group, South San Francisco, CA |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. | 2021 | European Stroke Journal |
Management of acute ST segment elevation myocardial infarction (STEMI). | 2019 | National Heart Association of Malaysia |
2019 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology guidelines on the acute management of st-elevation myocardial infarction: focused update on regionalization and reperfusion. | 2019 | The Canadian Journal of Cardiology |